Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 501–600 of 679
Kornegay, J. N., Stedman, H. H., Lawlor, M. W., Byrne, B. J., & Childers, M. K. (2024) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.28 · Cited by 3
Duchenne muscular dystrophy, one of the most complicated diseases for gene therapy
Braun, S. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2024.79 · Cited by 5
Progress and Challenges in AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy
Takeda, S., & Ok, T. (2011) · InTech eBooks · doi:10.5772/18624 · Cited by 2
“The first clinical gene therapy trial for DMD began in March 2006 (Mendell et al., 2010).”
Nowak, K. J., Lamont, P. J., & Laing, N. G. (2013) · Wiley eBooks · doi:10.1002/9781118635469.ch4 · Cited by 3
Neuromuscular diseases: milestones in development of treatments
Bushby, K. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70311-2 · Cited by 2
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Verma, A. (2011) · Yearbook of Neurology and Neurosurgery · doi:10.1016/j.yneu.2011.05.038 · Cited by 2
Ghirotto, B., Loures, F. V., Bueno, H. M. D. S., Cangussu, E., Goulart, E., Coatti, G. C., Caldini, E. T. E. G., Condino‐Neto, A., & Zatz, M. (2017) · European Journal of Human Genetics · doi:10.1038/s41431-017-0017-y · Cited by 3
“been reported in human DMD patients [25], GRMD dogs”
Gene Therapy for X-Linked Myotubular Myopathy
Dupont, J.-B., Lawlor, M. W., & Childers, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_32 · Cited by 2
Translational Medicine: Evolution, Fulfillment, and Belief in Gene Therapy
Mendell, J. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.29103.jrm · Cited by 2
Self-citationHoffman, E. P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00091-7 · Cited by 2
Gene Therapy in Monogenic Congenital Myopathies
Guan, X., Goddard, M. A., Mack, D. L., & Childers, M. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00013-9 · Cited by 2
Enzyme-Nanoparticle Corona: A Novel Approach, Their Plausible Applications and Challenges
Paul, M., Pandey, N. K., Shroti, G. K., Preeti, T., Thatoi, H., Bhattacharya, D., Banik, S. P., Ghosh, D., & Hazra, S. (2021) · Springer eBooks · doi:10.1007/978-981-33-4195-1_9 · Cited by 2
Development of viral & non-viral episomal vectors for gene therapy applications
Kymäläinen, H. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 3
Streppa, L. (2017) · theses.fr (ABES) · doi:10.70675/e42d405cz401az4abfz9d64ze4b2b127854d · Cited by 4
Use of Mesenchymal Stem Cells to Enhance the Efficacy of Gene Therapy
Hayashita‐Kinoh, H., & Okada, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2772-3_19 · Cited by 1
Keil, E. S., Schulze, M. L., Kitzberger, I., Schulze, V. H., Haveroth, C. H., Tuon, T., Webber, E. M., & Golçalves, M. V. M. (2023) · Translational Science of Rare Diseases · doi:10.3233/trd-220056 · Cited by 1
“According to Silva et al, 8% of female DMD-like disease carriers have symptoms [25], and the prevalence is 15.9–19.5 cases per 100,000 women [29], while in boys 1 in 3,500 is affected [20].”
InfluentialHan, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., Wu, H., Ma, S., Han, J., Bu, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04301-5 · Cited by 1
“Furthermore, the disordered immune microenvironment hampered the therapeutic response and clinical outcomes of many promising approaches aimed at restoring dystrophin (including stem cell transplantation, gene therapy, and exon skipping) [27, 28].”
BackgroundExploring new therapeutics for Duchenne muscular dystrophy and related cardiomyopathy
Li, B., Xiong, W., Chang, A. C. H., & Chang, A. C. Y. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.44 · Cited by 1
Käyhty, P., Nieminen, T., Eriksson, R. A. E., Tumelius, R., Tawfek, A., Laidinen, S., Ruotsalainen, A., Bailey, A., Galibert, L., Lesch, H. P., et al. (2026) · Gene Therapy · doi:10.1038/s41434-025-00588-9 · Cited by 1
“Disease-associated in fl ammation can increase transgene immunogenicity [17], although in some cases, IM gene transfer may promote a tolerogenic environment by promoting the activation and accumulation of regulatory T cells (Tregs) [22].”
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Gene Editing for Haemophilia—The Next Frontier
Pinotti, M., Newby, G. A., Selvaraj, S. R., & Pipe, S. W. (2026) · Haemophilia · doi:10.1111/hae.70238 · Cited by 1
Viral Gene Therapy in Skeletal Muscle: A Work in Progress
Lawlor, M. W. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000e109 · Cited by 1
Cardiac Complications of Neuromuscular Disorders
Spurney, C. F., & Schramm, J. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00003-2 · Cited by 1
The struggle to model muscular dystrophy
Kang, P. B. (2011) · Muscle & Nerve · doi:10.1002/mus.22124 · Cited by 1
Vvedensky, A. V., Sizova, S. V., & Kuzmich, A. I. (2015) · BIOPHYSICS · doi:10.1134/s0006350915050231 · Cited by 1
Innovative Therapeutic Perspectives in Neuromuscular Diseases
Cure, S., & Braun, S. (2012) · BioValley monographs · doi:10.1159/000339191 · Cited by 1
Gene and Cell Therapies for Muscular Dystrophies
Benedetti, S., Cossu, G., & Tedesco, F. S. (2015) · CRC Press eBooks · doi:10.1201/b18002-46 · Cited by 1
“[160].”
Report: Fourth International Workshop for Glycosylation Defects in Muscular Dystrophies
Blaeser, A. (2016) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000286 · Cited by 1
“The results of this study identified a potential for T-cell immunity to viral proteins and dystrophin transprotein as a consideration for future therapies [19].”
BackgroundBachtarzi, H., & Farries, T. (2016) · InTech eBooks · doi:10.5772/62282 · Cited by 1
“The efficiency of functional dystrophin expression in patients with DMD, using AAV as a vector, was assessed in a phase I clinical trial [10].”
BackgroundImmune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Martinet, J., Bourdenet, G., Meliani, A., Jean, L., Adriouch, S., Cohen, J. L., Mingozzi, F., & Boyer, O. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00360 · Cited by 1
“Furthermore, transgene-specific T CD8 + lymphocytes can destroy transduced cells and provoke failure of gene therapy as seen in preclinical animal models of hemophilia B (31, 32) and in clinical trials of gene therapy for muscular dystrophy (33).”
Ashley, S. N., Somanathan, S., Hinderer, C. J., Arias, M., McMenamin, D., Draper, C., & Wilson, J. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601131 · Cited by 1
“Previously, the field of gene therapy assumed that the complete absence of full-length protein expression because of null mutations results in a loss of tolerance via lack of Ag presentation (9).”
BackgroundGene therapy strategies for X-linked myotubular myopathy
Pierson, C. R. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1443807 · Cited by 1
Genome Editing Therapy for Duchenne Muscular Dystrophy
Gao, Y., Xu, L. M., & Han, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00014-4 · Cited by 1
Gene Replacement Therapy for Duchenne Muscular Dystrophy
Hollinger, K., Crudele, J. M., & Chamberlain, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_18 · Cited by 1
Immune System Regulation of Muscle Injury and Disease
Kastenschmidt, J. M., Mannaa, A. H., Muñoz, K. J., & Villalta, S. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_7 · Cited by 1
Design of Clinical Trials for Gene Therapy in Muscular Dystrophy
Quiroz, J. A., & Wagner, K. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_38 · Cited by 1
Genetic Determinant of Familial Dilated Cardiomyopathy and Genotype-Targeted Therapeutic Strategy
Zhong, J., Li, L.-P., Zhou, J., & Ding, Y. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94434 · Cited by 1
Muscular Dystrophy - Research Updates and Therapeutic Strategies
Gaina, G. F. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87261 · Cited by 1
Micro/mini-dystrophines et dystrophie musculaire de Duchenne : entre espoirs et défis
Lagrue, E., Cancès, C., & Ropars, J. (2021) · Les Cahiers de Myologie · doi:10.1051/myolog/202123004 · Cited by 1
Immune Responses to Adeno-Associated Virus-Mediated CRISPR Therapy
Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29193.amk · Cited by 1
“10 In addition, in an alpha-1-antityrpsin (AAT) deficiency clinical trial, immune responses resulting in reduced transgene expression were observed in one patient with a common single amino acid polymorphism that not re-presented in the wild-type transgene.”
Using Analogue Data to Substantiate Long-Term Durability of Gene Therapies: A Narrative Review
Sharpe, M. E., Beswick, L., & Kefalas, P. (2022) · Regenerative Medicine · doi:10.2217/rme-2021-0159 · Cited by 1
McMillan, H. J., & Lochmüller, H. (2023) · Muscle & Nerve · doi:10.1002/mus.28000 · Cited by 1
“The production of mini-dystrophin or micro-dystrophin in such cases has the potential to induce a late immune response 16 which has been associated with rhabdomyolysis and autoimmune myositis 17 as well as myocarditis.”
BackgroundRichard, I. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00221-x · Cited by 1
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Clark, R. D. E., Rabito, F., Munyonho, F. T., Remcho, T. P., & Kolls, J. K. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101286 · Cited by 2
Brandsema, J. F., & Darras, B. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00001-7 · Cited by 1
Challenges in developing gene therapy against Duchenne muscular dystrophy
Kurshakova, E. V., Levchenko, O. A., & Лавров, А. В. (2025) · Genes and Cells · doi:10.17816/gc641931 · Cited by 1
AAV-Mediated Exon Skipping for Duchenne Muscular Dystrophy
Benchaouir, R., & Goyenvalle, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_20 · Cited by 1
Barthélémy, I. (2010) · theses.fr (ABES) · doi:10.70675/b8b689c3z8c8bz4303z98fdz158787da1ba7 · Cited by 1
Measuring dystrophin—faster is not necessarily better
Arechavala‐Gomeza, V., Feng, L., Morgan, J. E., & Muntoni, F. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.15-c1 · Cited by 1
Bourhill, T. (2015) · Cited by 1
Bayazit, M. B., Henderson, D., Nguyen, K. T., Reátegui, E., Tawil, R., Flanigan, K. M., Harper, S. Q., & Saad, N. Y. (2024) · medRxiv · doi:10.1101/2024.11.29.24317861 · Cited by 1
Eghtesad, S. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Immunological Components of Genetically Inherited Muscular Dystrophies
Spencer, M. J., Kramerova, I. A., Miceli, M. C., & Nagaraju, K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00078-8
Sohn, J. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Genetic Therapy for Duchenne Muscular Dystrophy: Principles and Progress
Koo, T., Popplewell, L. J., Malerba, A., & Dickso, G. (2012) · InTech eBooks · doi:10.5772/29617 · Cited by 1
“However, microdystrophin expression was only detected in two of six patients treated at very low levels and two patients exhibited pre-existing dystrophin specific T cells (Mendell et al., 2010).”
BackgroundStrategies for improving adeno-associated viral infection of airway epithelial cells
Dickey, D. D. (2012) · doi:10.17077/etd.m1aiqczb
“rheumatoid arthritis (71-73), cardiac disease (74, 75), Duchenne’s muscular dystrophy (76), and limb-girdle muscular dystrophy (77, 78), with varying degrees of success.”
BackgroundDuchenne Muscular Dystrophy: Therapeutic Approaches to Restore Dystrophin
Spitali, P., & Aartsma-Rus, A. M. (2012) · InTech eBooks · doi:10.5772/31232
“A clinical study has been also carried out in 6 DMD patients (aged 5-11 years) who received an intramuscular injection into the biceps muscle of a recombinant AAV (rAAV) vector carrying a μDYS gene (Mendell et al., 2010).”
MethodAdvancing the evidence base for nutritional management of boys with Duchenne muscular dystrophy
Davidson, Z. E. (2017) · Figshare · doi:10.4225/03/58980a63b11b6
From structure and dynamics to novel therapeutic development for muscular dystrophy.
Lin, A. Y. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Vieira, N. M. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2011.tde-12052011-141339
Steines, B. R., Zabner, J., Meier, J. L., Adams, C. M., McCray, P. B., & Yeaman, C. A. (2015) · doi:10.17077/etd.tdj11wfe
Valadares, M. C. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2014.tde-16042014-145819
A review of Duchenne muscular dystrophy focusing on cardiac involvement
Wright, S. (2014) · PEARL (University of Plymouth) · doi:10.24382/n0vn-3805
Biotherapies of neuromuscular disorders
Briand, J.-F., Roy, M.-O., Mourlane, F., André, C., Loux, N., Rougeau, C., Toursel, T., & Braun, S. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.07.018
Kwok, Y. (2014) · eScholarship (California Digital Library)
Gene Therapy for Hereditary Hearing Loss
McDougald, D. S., Cunningham, L. L., & Chien, W. W. (2013) · Perspectives on Hearing and Hearing Disorders Research and Diagnostics · doi:10.1044/hhd17.1.5
Satellite Cells and Their Potential for Therapy in Muscular Dystrophies
García, J. (2012) · Journal of Physical Chemistry & Biophysics · doi:10.4172/2161-0398.1000e109
“In general, the aim of gene therapy is to deliver a copy of the defective gene carried by viral vectors [2,3] or to restore the reading frame (exon skipping) with antisense oligonucleotides [48].”
BackgroundStem Cells for the Treatment of Muscular Dystrophy
Tedesco, F. S., Sampaolesi, M., & Cossu, G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385942-6.00056-1
Crain, J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Biophysical, cellular, and animal models of dystrophin missense mutations
Talsness, D. M. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Hepatic stellate cell transdifferentiation: Pro-fibrogenic effectors
Lakner, A. M., & NC DOCKS at The University of North Carolina at Charlotte (2011) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro)
The New Frontier of Genetically Targeted Therapies for Muscle Disease
Kang, P. B. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000440666.79792.84
“A human trial of gene therapy for Duchenne muscular dystrophy identified an immune response to the donor dystrophin protein, a complication that may limit the efficacy of this intervention as currently designed.(24) Therefore, the family should consider the potential harms to both the patient and the family from parti…”
BackgroundTalan, J. (2010) · Neurology Today · doi:10.1097/01.nt.0000390834.89099.d5
Regenerative Medicine Approaches to Degenerative Muscle Diseases
Childers, M. K., & Wang, Z. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-3228-3_1 · Cited by 1
Schindl, R., Mayer, K., & Aigner, K. (1975) · PubMed
Principles and Practice of Molecular Therapies
Rodino‐Klapac, L. R., & Mendell, J. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00051-2
Self-citationAl-Rewashdy, H. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-6527
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
“…telles observations ont pu également être faites lorsque le muscle était ciblé par ces vecteurs dans le cadre d’études cliniques de thérapie génique (Brantly et al., 2009; Flotte et al., 2005, 2011; Herson et al., 2012; Jaski et al., 2009; Mendell et al., 2009, 2010a, 2010b; Mingozzi et al., 2009).”
BackgroundGojanovich, G. S. (2014) · NCSU Libraries Repository (North Carolina State University Libraries)
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
Treatment of Duchenne Muscular Dystrophy: A Comprehensive Review
Park, H. J., & Choi, Y. (2012) · Journal of the Korean Neurological Association
Duan, D., Emter, C. A., Lai, Y., Yang, H. T., Hakim, C. H., & Yue, Y. (2015)
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58 · Cited by 1
Odiba, A. S., Ottah, V., Anunobi, O. O., Ukegbu, C. Y., Uroko, R. I., Ottah, C., Edeke, A. A., & Omeje, K. O. (2017) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2017.07.005 · Cited by 1
“For instance, the reactivation of memory T-cell responses which results in the loss of vectormodified cells, providing the attenuation therapeutic efficacy, as opposed to the muscle- and liver-directed gene therapy applications [18,33], subretinal injection of AAV vectors would mount low humoral immune responses.”
BackgroundC URRENT OPINION Gene therapy for Duchenne muscular dystrophy
Aartsma-Rus, A. M. (2012)
CRISPR/Cas9 for the Correction of Mutated Dystrophin Gene
Manger, P. T. (2016) · Skemman
Thérapie génique du diabète de type 1 : quelles avancées ?
Dubois‐Laforgue, D. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70785-0
Xiao, P. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rn9x-xq74
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
Sperringer, J. E. (2019) · VTechWorks (Virginia Tech)
Robinson, R. (2019) · Neurology Today · doi:10.1097/01.nt.0000617152.42093.e9
Delineation of Duchenne muscular dystrophy gene therapy using genetically engineered mice
Wasala, N. B. (2016) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/57275
Al-Zaidy, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821635-4.00037-0
Cell disorders in lysosomal storage diseases
Roy, E. (2012) · theses.fr (ABES) · doi:10.70675/bf977698z4d47z4ca2zbf59zf7160f091f3d · Cited by 1
Luzzatto, L. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13409045.15186056
Taylor, M. B. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738401805.793578644
(2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834dd969
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.